– Strengthens intellectual property portfolio for macimorelinand thecommercial product Ghryvelin®/Macrilen™in Europe as the Company plans to pursue even greater protection
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.